KLK3 and prostate carcinoma: A phase II trial observed that the use of high-dose metformin in mCRPC reduced PSA secretion and delayed the progression of prostate cancer [27].A cohort study based on a prostate cancer population showed that patients with hyperlipidemia may have prolonged survival with metformin and statins while undergoing radiotherapy [28].